Predictors of invasive disease in patients preoperatively diagnosed with ductal carcinoma without stromal invasion, with breast magnetic resonance imaging (MRI) and ultrasound (US)

[1]  S. Mclaughlin,et al.  A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease , 2017, Annals of Surgical Oncology.

[2]  L. Strobbe,et al.  Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy , 2016, Breast Cancer Research and Treatment.

[3]  H. Tsunoda,et al.  A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast , 2015, Journal of surgical oncology.

[4]  W. Barry,et al.  Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study. , 2015, JAMA surgery.

[5]  C. Ryan,et al.  Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. , 2015, Breast.

[6]  F. Akiyama,et al.  Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ , 2014, Cancer science.

[7]  V. Ozmen,et al.  Factors predicting microinvasion in Ductal Carcinoma in situ. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[8]  C. Coutant,et al.  Impact of sentinel node biopsy on long-term quality of life in breast cancer patients , 2013, British Journal of Cancer.

[9]  T. Taguchi,et al.  Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ. , 2011, American journal of surgery.

[10]  S. Ciatto,et al.  Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. , 2011, Radiology.

[11]  D. Blackhurst,et al.  The Use of Sentinel Lymph Node Biopsy in Ductal Carcinoma in Situ , 2010, The American surgeon.

[12]  R. Kane,et al.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. , 2010, Journal of the National Cancer Institute.

[13]  M. Sherman,et al.  Recent trends in breast cancer among younger women in the United States. , 2008, Journal of the National Cancer Institute.

[14]  P. Del Bianco,et al.  Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  M. Kerin,et al.  Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. , 2007, American journal of surgery.

[16]  J. Peterse,et al.  Sentinel lymph node biopsy in staging small (up to 15 mm) breast carcinomas. Results from a European multi-institutional study , 2007, Pathology & Oncology Research.

[17]  E. Wight,et al.  Morbidity of Sentinel Lymph Node Biopsy (SLN) Alone Versus SLN and Completion Axillary Lymph Node Dissection After Breast Cancer Surgery: A Prospective Swiss Multicenter Study on 659 Patients , 2007, Annals of surgery.

[18]  D. McCready,et al.  Role of Sentinel Lymph Node Biopsy in Ductal Carcinoma-in-situ Treated by Mastectomy , 2007, Annals of Surgical Oncology.

[19]  U. Chetty,et al.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. , 2006, Journal of the National Cancer Institute.

[20]  R. Mansel,et al.  Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases , 2006, Breast Cancer Research and Treatment.

[21]  Sheryl G. A. Gabram,et al.  Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial , 2006, Annals of Surgical Oncology.

[22]  S. Duffy,et al.  Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Singletary,et al.  Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. , 2005, Journal of the American College of Surgeons.

[24]  E. Mittendorf,et al.  Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. , 2005, Current surgery.

[25]  A. Luini,et al.  Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. , 2003, Archives of surgery.

[26]  D. Reintgen,et al.  Importance of Lymphatic Mapping in Ductal Carcinoma in Situ (DCIS): Why Map DCIS? , 2001, The American surgeon.

[27]  A. Muzikansky,et al.  The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma , 2002, Annals of Surgical Oncology.

[28]  L. Liberman,et al.  Sentinel Lymph Node Biopsy: Is It Indicated in Patients With High-Risk Ductal Carcinoma-In-Situ and Ductal Carcinoma-In-Situ With Microinvasion? , 2000, Annals of Surgical Oncology.

[29]  D. Reintgen,et al.  Sentinel Node Biopsy in Ductal Carcinoma In Situ Patients , 2000, Annals of Surgical Oncology.